// App-Quantinova.ai

16787 : Use of Thienopyridine Prior to Presentation for Acute Coronary Syndromes and Association With Safety and Efficacy of Vorapaxar: Insights From the TRACER Study

Researchers

Presenter

  • Giuseppe Ambrosio

Principal Investigators

  • Robert Clare

  • Robert Harrington

  • Frans Van de Werf

  • Lars Wallentin

  • John Strony

  • Pierluigi Tricoci

  • Claes Held

  • Yuliya Lokhnygina

  • David Moliterno

  • Harvey White

  • Philip Aylward

  • SAHMRI

  • Paul Armstrong

  • Kenneth Mahaffey

Medical Centers

  • Duke Clinical Res Inst, Duke Univ Medical Ctr, Durham, NC

  • Uppsala Clinical Res Ctr, Uppsala Univ, Uppsala, Sweden

  • Green Lane Cardiovascular Service, Auckland, New Zealand

  • Duke Clinical Research Institute, Durham, NC

  • Univ of Perugia Sch of Med, Perugia, Italy

  • Univ. of Alberta, Edmonton, Alberta, Canada.

  • Gill Heart Inst and Univ of Kentucky, Lexington, KY

  • Uppsala Clinical Research Center, Uppsala, Sweden

  • KU Leuven, Leuven, Belgium

  • Flinders University Medical Centre, Adelaide, Australia

Locations

  • Canada

  • Italy

  • Australia

  • United States

  • Belgium

  • Sweden

  • New Zealand

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Acute Coronary Syndromes

  • Myocardial infarction

  • Coronary Artery Disease

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Vorapaxar

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved